Should Androgen Receptor Targeting Be Given Earlier for Prostate Cancer?

Charles J. Ryan, MD

Charles J. Ryan, MD, University of California, discusses the advantages of giving androgen receptor targeting earlier to advanced disease patients, and a review of the STAMPEDE results.

To view slides from Dr. Ryan’s androgen receptor presentation at the 18th Annual Future Directions in Urology Symposium, click here.

To view slides from Dr. Ryan’s STAMPEDE results presentation at the 18th Annual Future Directions in Urology Symposium, click here.

“Keywords: prostate cancer, androgen receptor, STAMPEDE

ABOUT THE AUTHOR

Charles J. Ryan, MD

Charles J. Ryan, MD, is an internationally recognized genitourinary (GU) oncologist at the Sidney Kimmel Center for Prostate and Urologic Cancers in New York City and at Memorial Sloan Kettering Monmouth in New Jersey. He has expertise in the biology and treatment of and supportive care of all men with prostate cancer. Dr. Ryan earned a BA in Philosophy, magna cum laude, from Marquette University and graduated from the University of Wisconsin Medical School.

About The Author

Charles J. Ryan, MD

Charles J. Ryan, MD, is an internationally recognized genitourinary (GU) oncologist at the Sidney Kimmel Center for Prostate and Urologic Cancers in New York City and at Memorial Sloan Kettering Monmouth in New Jersey. He has expertise in the biology and treatment of and supportive care of all men with prostate cancer. Dr. Ryan earned a BA in Philosophy, magna cum laude, from Marquette University and graduated from the University of Wisconsin Medical School. He trained at the University of Wisconsin Hospital and Clinics and at Memorial Sloan Kettering Cancer Center. As faculty at the University of California, San Francisco, he was named the Thomas Perkins Distinguished Professor in Cancer Research. He has received research funding from the National Institutes of Health, the Department of Defense Prostate Cancer Research Program, and the Prostate Cancer Foundation. Ryan has published over 200 articles and chapters in the world’s leading medical journals and is the author of the book The Virility Paradox: The Vast Influence of Testosterone on Our Bodies, Minds, and the World We Live In. Dr. Ryan is a past Chair of the National Cancer Institute’s GU Steering Committee’s Prostate Cancer Task Force. From 2018 to 2021, he served as Director of the Division of Hematology, Oncology, and Transplantation at the University of Minnesota, where he was the BJ Kennedy Chair in Clinical Oncology. From 2021 to 2024, Ryan served as the CEO of the Prostate Cancer Foundation (PCF). He currently serves on the Scientific Oversight Committee of the Prostate Cancer Clinical Trials Consortium (PCCTC).

Share This